Immune to Cancer: The CRI Blog
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
CICON16: The Future of Cancer Immunotherapy
CICON16 ended by focusing on emerging treatments and technologies in cancer immunotherapy.
-
CICON16: The Power of Combinations
Targeting tumors from multiple angles improves our odds of success.
-
CICON16: Bacteria and Cancer Immunity
New research shows that bacteria within us can influence both the development of cancer and the immune…
-
CICON16: Corrupted by Cancer
Day 2 of CICON16 explored strategies to overcome challenges within the tumor microenvironment.
-
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints
The latest advances in using new checkpoint drugs to target LAG-3, Nrp1, IL-35R, CD36, and mitochondrial metabolism.
-
CICON16: Cancer Antigens and the Development of Personalized Immunotherapy Approaches
Antigens are the key to effective vaccines and the immune system’s ability to target cancer cells.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.